The reading room / Peptide research blog

Peptide research, explained.

Detailed guides to peptide identity, biological pathways, analytical methods and clinical evidence. Search the reading room or follow a research topic.

Browse 13 research topics
Reset filters

All guides & articles

85–96 of 149 guides

Page 8 of 13
Close-up research assay plate with cAMP and Other readouts document tabs in a GLP-1 signaling dossier, in the Ecnoglutide research file.Research Practice

Ecnoglutide: What cAMP-Biased GLP-1 Signaling Means

Ecnoglutide is described as a cAMP-biased GLP-1 receptor agonist. That is a statement about signaling in an assay, not a clinical verdict that the molecule works better than all other GLP-1 medicines.

Updated 2026-10-29 ↗
anatomical heart and kidney teaching specimens beside an outcome-trial evidence ledger, in the Efpeglenatide research file.Research Practice

Efpeglenatide: Reading the AMPLITUDE-O Outcome Trial

AMPLITUDE-O evaluated efpeglenatide in people with type 2 diabetes and high cardiovascular or kidney-related risk.

Updated 2026-10-29 ↗
Eloralintide research file with an assay plate, amylin index slip and a 48-week follow-up register.Research Practice

Eloralintide: Selective Amylin Design and the 48-Week Trial

Eloralintide research links a molecular design question with a human weight-management question.

Updated 2026-10-29 ↗
Separated cell-membrane teaching sections and a fusion-step research envelope in an enfuvirtide archive file.Peptide Fundamentals

Enfuvirtide: A Peptide That Targets HIV Fusion

Enfuvirtide is a peptide antiretroviral that targets a stage of HIV-1 entry: fusion of viral and cellular membranes.

Updated 2026-10-29 ↗
Single platelet teaching specimen in the center of two identity files Eptifibatide and Tirofiban, with one IIb/IIIa index tab, in the Eptifibatide vs Tirofiban research file.Peptide Fundamentals

Eptifibatide vs Tirofiban: Same Platelet Target, Different Molecules

Eptifibatide and tirofiban act at platelet glycoprotein IIb/IIIa, yet their structures are different: eptifibatide is a cyclic peptide and tirofiban is a nonpeptide antagonist.

Updated 2026-10-29 ↗
Archival scientific-name genealogy file with a Exendin-4 source identity card and a Exenatide medicine-identity research card, with a GLP-1 index tab, in the Exenatide and Exendin-4 research file.Peptide Fundamentals

Exenatide and Exendin-4: A Different GLP-1 Peptide Design

Exenatide is related to exendin-4 and acts at the GLP-1 receptor, but the product’s formulation remains central to its evidence.

Updated 2026-10-29 ↗
Chronological study-visit archive calendar beside an unused clinical support bag and a primary-endpoint record sleeve, in the Glepaglutide research file.Research Practice

Glepaglutide: What the EASE SBS-1 Trial Measured

EASE SBS-1 measured whether glepaglutide reduced parenteral support needs in people with short bowel syndrome and intestinal failure.

Updated 2026-10-29 ↗
gallbladder and bile-duct teaching specimen in a shallow conservation case beside a biliary safety-event folder, in the GLP-1 Drugs and Gallbladder Events research file.Research Practice

GLP-1 Drugs and Gallbladder Events: What the Studies Show

A gallstone, gallbladder inflammation and obstruction of the biliary tract are related outcomes, but they are not interchangeable.

Updated 2026-10-29 ↗
anatomical stomach teaching model beside three short archive tabs Emptying, Symptoms, Diagnosis, in the GLP-1 Drugs and Gastroparesis research file.Research Practice

GLP-1 Drugs and Gastroparesis: Delay, Symptoms and Diagnosis

Delayed gastric emptying is a measured physiological effect. Gastroparesis is a clinical diagnosis that requires more context than a delayed measurement alone.

Updated 2026-10-29 ↗
Detailed monochrome photographic print of an unoccupied DXA scanner, held by archival corners, with Lean mass and Fat mass index slips, in the GLP-1 Weight Loss and Muscle Loss research file.Research Practice

GLP-1 Weight Loss and Muscle Loss: What DXA Can Tell You

A headline about GLP-1 muscle loss may be describing a DXA estimate of lean tissue, the proportion of lost weight classified as lean, or a direct measure of strength.

Updated 2026-10-29 ↗
Two distinct clinical context files: a glucose-rescue laboratory sample photograph and a metabolic receptor-research assay photograph, in the Glucagon research file.Peptide Fundamentals

Glucagon: Why Rescue Medicine and Metabolic Coagonism Differ

Glucagon rescue medicines and glucagon-containing metabolic coagonists use a related biological pathway to answer different clinical questions.

Updated 2026-10-29 ↗
Detailed vessel-wall teaching model with an interstitial-fluid research compartment, partly revealed from a Bradykinin receptor dossier, in the Icatibant research file.Peptide Fundamentals

Icatibant: Why Bradykinin-Mediated Angioedema Is a Different Target

Icatibant targets the bradykinin B2 receptor. That mechanism is why its hereditary-angioedema evidence should be read separately from familiar allergy narratives centered on histamine.

Updated 2026-10-29 ↗
Peptide Research Guides & Evidence: Page 8 | PeptideTwo